Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1179839 | Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics | 2013 | 11 Pages |
In this article, we are reviewing the molecular mechanisms that lead to kinase inhibitor resistance. As the oncogenic BCR-ABL kinase is the target of the first approved small-molecule kinase inhibitor imatinib, we will first focus on the structural and mechanistic basis for imatinib resistance. We will then show ways how next generations of BCR-ABL inhibitors and alternative targeting strategies have helped to offer effective treatment options for imatinib-resistant patients. Based on these insights, we discuss commonalities and further mechanisms that lead to resistance to other kinase inhibitors in solid tumors. This article is part of a Special Issue entitled: Inhibitors of Protein Kinases (2012).
► We describe the mode of action of the BCR-ABL kinase inhibitor imatinib. ► Different mechanisms leading to imatinib resistance are discussed. ► New generations of BCR-ABL inhibitors are presented. ► Resistance mechanisms to other approved kinase inhibitors are described.